Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 110, Issue 29, Pages 12018-12023
Publisher
Proceedings of the National Academy of Sciences
Online
2013-07-02
DOI
10.1073/pnas.1301331110
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design
- (2012) Edward B. Garon et al. Clinical Lung Cancer
- Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial
- (2012) Rodryg Ramlau et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib and the treatment palette for soft-tissue sarcoma
- (2012) Vivien HC Bramwell LANCET
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity
- (2011) D. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cardiovascular toxicity of anti-angiogenic drugs
- (2011) Gaetan des Guetz et al. Targeted Oncology
- Ramucirumab (IMC-1121B): a novel attack on angiogenesis
- (2010) Jennifer L Spratlin et al. Future Oncology
- Bevacizumab toxicities and their management in ovarian cancer
- (2010) Leslie M. Randall et al. GYNECOLOGIC ONCOLOGY
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Taming Glioblastoma by Targeting Angiogenesis: 3 Years Later
- (2010) Eric T. Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models
- (2010) Yanlan Yu et al. PLoS One
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy
- (2009) R. Cao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
- (2009) Y. Cao Science Signaling
- Hypertension and proteinuria: a class-effect of antiangiogenic therapies
- (2008) Vincent Launay-Vacher et al. ANTI-CANCER DRUGS
- Les antiangiogéniques en oncologie digestive
- (2008) A. Lièvre et al. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
- Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
- (2008) J. Tol et al. INVESTIGATIONAL NEW DRUGS
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
- Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome
- (2008) Y. Xue et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started